drugset
drugset / Trial / NCT00624585

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

NCT00624585 ↗

Completed 18 enrolled H. Lee Moffitt Cancer Center and Research Institute Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to learn how patients with myelodysplastic syndrome (MDS) respond to the study drug dasatinib. The study drug, dasatinib, has been approved by the U.S. Food and Drug Administration (FDA) for treatment of leukemia, but has not been approved for the treatment of other kinds of cancer. The use of dasatinib in this study is considered experimental.

Timeline

Start
2008-02
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject dasatinib anhydrous Small molecule 50 mg Oral
Subject dasatinib anhydrous Small molecule 70 mg Oral
Subject dasatinib anhydrous Small molecule 90 mg Oral
Subject dasatinib anhydrous Small molecule 100 mg Oral
Subject dasatinib anhydrous Small molecule 120 mg Oral
Subject dasatinib anhydrous Small molecule 150 mg Oral

Indications

myelodysplastic syndrome